In the latest trading session, Novavax (NVAX) closed at $12.82, marking a +1.26% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.02%. On the other hand, ...

Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that ...

Novavax has delivered a sharp mix of gains and losses over the years, and the recent rebound puts fresh attention on a basic ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at ...

Wall Street regained some momentum on Friday, after the AI trade came under pressure on Thursday. The S&P 500 (SP500) closed up 0.59%, the Dow (DJI) jumped 0.83%, and the Nasdaq Composite (COMP:IND) ...

Novavax jumped on plague fears, but weak finances and no clear drug path remain. Click here to read this latest analysis of ...

Novavax (NVAX) stock surged 16% after Sanofi’s combination vaccine trial cleared key European approvals, triggering a ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as ...

Novavax, Moderna and other vaccine stocks rallied after a lab worker in Russia died following suspected plague exposure, WHO ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76 ...

Novavax benefited from this deal, but moving forward, there is far too much uncertainty surrounding it. For one, demand for coronavirus vaccines might no longer be what it once was. That's on top of ...